/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Company Overview We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing th…
$0.96
+$0.00 (+0.21%)
EOD Sep 18, 2026
ROIC dropped from -40.50% to -45.43%, capital efficiency is deteriorating. Negative free cash flow of -$60M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$35M
▲ +13.7% YoY
Op. Margin
—
ROIC
-36.56%
▼ -4.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$30M
▼ -6.8% YoY
Op. Cash Flow (TTM)
-$30M
▼ -7.3% YoY
Net Debt
-$22M
Net Cash Position
Cash & Equiv.
$22M
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 1 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.